Issue of Equity

22 October 2012

Akers Biosciences, Inc.

("ABI" or the "Company")

Issue of Equity

Akers Biosciences, Inc (AIM: AKR), announces that an employee has purchased 100,000 shares under the AB Direct Stock Purchase Plan.

Application for admission to trading on AIM for these 100,000 shares has been made and admission is expected to occur on 24 October 2012.

Following this issue of shares, the Company has 198,815,666 common shares in issue and 10,000,000 preferred shares in issue. The Preferred Shares each have five votes per share and the Company has no ordinary shares held in treasury. The total number of voting rights in the Company is therefore 248,815,666. This figure may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the voting capital of the Company under the FSA's Disclosure and Transparency Rules.

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Antony Legge / Emma Earl

Daniel Stewart (Nomad and Broker)

Tel. +44 (0)20 7776 6550

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com